DexCom (DXCM) to Release Earnings on Thursday

DexCom (NASDAQ:DXCM) is anticipated to issue its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $0.65 per share and revenue of $1.2520 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

DexCom Price Performance

DXCM opened at $70.83 on Thursday. The stock has a fifty day simple moving average of $68.39 and a two-hundred day simple moving average of $70.50. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. The company has a market cap of $27.63 billion, a price-to-earnings ratio of 39.35, a price-to-earnings-growth ratio of 1.28 and a beta of 1.49. DexCom has a 12-month low of $54.11 and a 12-month high of $93.25.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach acquired 18,200 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was purchased at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the acquisition, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $59.05, for a total transaction of $171,599.30. Following the sale, the director owned 35,088 shares of the company’s stock, valued at approximately $2,071,946.40. This represents a 7.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 7,866 shares of company stock worth $448,177 over the last three months. 0.32% of the stock is currently owned by company insiders.

Institutional Trading of DexCom

Several large investors have recently added to or reduced their stakes in the business. Brighton Jones LLC raised its stake in DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the period. L2 Asset Management LLC purchased a new position in shares of DexCom in the third quarter worth $274,000. Boothbay Fund Management LLC bought a new position in shares of DexCom during the third quarter worth $216,000. Algert Global LLC bought a new position in shares of DexCom during the third quarter worth $344,000. Finally, Freestone Grove Partners LP purchased a new position in DexCom during the third quarter valued at $219,000. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. UBS Group decreased their price target on shares of DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, November 3rd. Robert W. Baird set a $82.00 target price on shares of DexCom in a research note on Friday, October 31st. Piper Sandler set a $75.00 target price on shares of DexCom and gave the company a “buy” rating in a report on Friday, October 31st. Canaccord Genuity Group set a $99.00 price target on DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Barclays lowered DexCom from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $80.00 to $71.00 in a research report on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $85.00.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.